➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Express Scripts
Mallinckrodt
Merck
Boehringer Ingelheim

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,872,739

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,872,739
Title: Use of riluzole for the treatment of multiple sclerosis
Abstract:Methods for the treatment of multiple sclerosis are disclosed comprising administering 6-(triflouromethoxy)-2-benzothiazolamine or a salt thereof.
Inventor(s): Polman; Chris (Overveen, NL)
Assignee: Vereniging Voor Christelijk Wetenshappelikjk Onderwijs (Amsterdam, NL)
Application Number:09/926,693
Patent Claims:1. A method for the treatment of multiple sclerosis, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

2. The method of claim 1 wherein said pharmaceutical composition comprises a pharmaceutically effective carrier.

3. The method of claim 1 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent.

4. The method of claim 3 wherein said additional agent is selected from the group consisting of interferon beta-1a, interferon beta-1b, and copaxone.

5. The method according to claim 1 wherein the amount of 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 10 and about 500 mg per day.

6. The method of claim 5 wherein the amount of 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 50 and about 250 mg per day.

7. The method of claim 1, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

8. The method of claim 1, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

9. A method for treating a patient suffering from multiple sclerosis comprising the step of administering a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof in an amount effective to inhibit, minimize or delay the development of spinal cord atrophy associated with multiple sclerosis.

10. The method of claim 9 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent selected from the group consisting of interferon beta-1b, interferon beta-1a, and copaxone.

11. The method of claim 9, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

12. The method of claims 9, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

13. A method for the treatment of a patient suffering from multiple sclerosis comprising the steps of administering to said patient: a. a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof; and b. a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of interferon beta-1b, interferon beta-1a, and copaxone.

14. The method of claim 13, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine.

15. The method of claim 13, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

16. A method for the treatment of a patient suffering from primary progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

17. The method of claim 16 further comprising the administration of a therapeutically effective amount of interferon beta-1b, copaxone and interferon beta-1a.

18. The method of claim 16, wherein the composition comprises 6trifluoromethoxy)-2-benzothiazolamine.

19. The method of claim 16, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

20. A method for the treatment of a patient suffering from secondary-progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

21. The method of claim 20, wherein the composition comprises 6-(triflouromethoxy)-2-benzothiazolamine.

22. The method of claim 20, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

23. A method for the treatment of a patient suffering from relapsing-remitting multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof.

24. The method of claim 23, wherein the composition comprises 6-(triflouromethoxy)-2-benzothiazolamine.

25. The method of claim 23, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
99201788Jun 04, 1999
PCT Information
PCT FiledJune 02, 2000PCT Application Number:PCT/IB00/00933
PCT Publication Date:December 14, 2000PCT Publication Number:WO00/74676

Details for Patent 6,872,739

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Vereniging Voor Christelijk Wetenshappelikjk Onderwijs (Amsterdam, NL) 2019-06-04 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Vereniging Voor Christelijk Wetenshappelikjk Onderwijs (Amsterdam, NL) 2019-06-04 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Vereniging Voor Christelijk Wetenshappelikjk Onderwijs (Amsterdam, NL) 2019-06-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Express Scripts
Harvard Business School
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.